| Drug Name |
Remifentanil hydrochloride |
| Drug ID |
BADD_D01923 |
| Description |
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia. |
| Indications and Usage |
For use during the induction and maintenance of general anesthesia. |
| Marketing Status |
approved |
| ATC Code |
N01AH06 |
| DrugBank ID |
DB00899
|
| KEGG ID |
D01177
|
| MeSH ID |
D000077208
|
| PubChem ID |
60814
|
| TTD Drug ID |
D0T5OX
|
| NDC Product Code |
48954-724; 63323-723; 67457-912; 72078-035; 0143-9392; 50683-0550; 63323-724; 67457-198; 72078-036; 0143-9391; 67457-914; 12502-5343; 67457-913; 63323-725; 72078-034; 0143-9393 |
| UNII |
5V444H5WIC
|
| Synonyms |
Remifentanil | 3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic Acid Methyl Ester | Remifentanil Hydrochloride | Ultiva | Remifentanil Monohydrochloride | GI 87084B | GI87084B | GI-87084B |
